Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice

BACKGROUND: Children with recurrent and/or metastatic osteosarcoma (OS), neuroblastoma (NB) and glioblastoma multiforme (GBM) have a dismal event-free survival (<25%). The majority of these solid tumors highly express GD2. Dinutuximab, an anti-GD2 monoclonal antibody, significantly improved event...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yaya, Nayyar, Gaurav, Jiang, Susiyan, Rosenblum, Jeremy M., Soon-Shiong, Patrick, Safrit, Jeffrey T, Lee, Dean A., Cairo, Mitchell S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268924/
https://www.ncbi.nlm.nih.gov/pubmed/34244307
http://dx.doi.org/10.1136/jitc-2020-002267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268924/
https://www.ncbi.nlm.nih.gov/pubmed/34244307
http://dx.doi.org/10.1136/jitc-2020-002267

Ejemplares similares